A Multicenter, Double-blind, Placebo-controlled, Randomized, Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
Latest Information Update: 24 Jun 2024
Price :
$35 *
At a glance
- Drugs JNJ-67484703 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 28 Jun 2023 Status changed from active, no longer recruiting to completed.
- 11 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2023 Planned primary completion date changed from 17 Nov 2022 to 9 May 2023.